Search the Newsreel

Theravance Biopharma (TBPH): Newtyn discloses 6.7% holdings in amended 13G/A

Newtyn Management, LLC has disclosed a 6.7% beneficial ownership in Theravance Biopharma (TBPH) through an amended Schedule 13G filing. While Newtyn TE Partners, LP, a part of Newtyn Management, has reduced its holdings to below the 5% reporting threshold, Newtyn Management itself remains above …

Theravance Biopharma (TBPH) investor group reports 17.7% beneficial stake

An investor group led by Madison Avenue International LP has reported a 17.7% beneficial stake in Theravance Biopharma, Inc. (TBPH) as of June 30, 2026. This ownership, comprising 9,212,252 Ordinary Shares, is based on 51,918,754 outstanding shares as of July 31, 2026. The group, …

Theravance Biopharma (TBPH) Stock Caught Between Fading Gains And Royalty Doubts

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

Theravance Biopharma TBPH reported second-quarter 2026 adjusted earnings of 19 cents per share, matching the Zacks Consensus Estimate. In the year-ago quarter, the company had incurred an adjusted loss of 8 cents per share. Total revenues in the quarter were $20.7 million, marginally beating …

Theravance Biopharma, Inc. 2026: Revenue $20.73M, EPS ($0.11) — 10-Q Summary

Theravance Biopharma, Inc. (TBPH) reported its 2026 quarterly results, showing a significant decrease in revenue and a net loss compared to the prior year. Revenue dropped by 20.9% to $20.73M, resulting in a diluted EPS of ($0.11) versus $1.08 previously, largely due to the …

Renaissance Technologies LLC Acquires New Holdings in Theravance Biopharma, Inc. $TBPH

Renaissance Technologies LLC has acquired a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH), purchasing 127,916 shares valued at approximately $2.076 million. This makes Renaissance Technologies LLC one of many institutional investors with holdings in TBPH, as they collectively own 99.10% of the company's stock. …

Press Release: Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Theravance Biopharma, Inc. (TBPH) reported its second quarter 2026 financial results, highlighting a significant 15% increase in total revenue year-over-year, reaching $40 million. The company's net loss decreased by 10% to $18 million, or $0.30 per share, demonstrating improved financial performance. Key updates included …

Theravance Biopharma earnings missed by $0.17, revenue fell short of estimates

Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Meets Expectations

Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings per share of $0.07, matching analysts' consensus estimates. The company showed a strong return on equity of 18.84% and a net margin of 104.34%. Analysts currently maintain a "Hold" rating on the stock with a consensus price target …

Theravance Biopharma Q2 net loss turns to USD 5.9 million; revenue rises 11% to USD 20.7 million YoY

Theravance Biopharma reported a Q2 GAAP net loss of USD 5.9 million, a swing from a profit in the prior year, despite an 11% increase in revenue to USD 20.7 million, primarily from the Viatris collaboration. The company also saw reduced R&D and SG&A …

Is Theravance Biopharma Inc (TBPH) Undervalued After Q2 Earnings

Theravance Biopharma Inc (TBPH) released its Q2 2026 earnings, reporting an 11% increase in YUPELRI collaboration revenue to $20.7 million and a 35% reduction in operating expenses. Despite these gains and a solid cash balance, the company faces challenges, including a failed Phase 3 …

Earnings Flash (TBPH) Theravance Biopharma, Inc. Reports Q2 Revenue $20.7M, vs. FactSet Est of $22.5M

Theravance Biopharma, Inc. (TBPH) announced its Q2 revenue of $20.7 million, falling short of FactSet's estimate of $22.5 million. The company's stock was trading at 16.90 USD, reflecting a slight dip in performance. Theravance Biopharma specializes in developing and commercializing medicines for respiratory and …

Earnings Flash (TBPH) Theravance Biopharma Posts Q2 Net Loss $0.11 a Share, vs. FactSet Est of $0.07 EPS

Form 8K Theravance Biopharma Inc For: 10 August By Investing.com

This article announces that Theravance Biopharma Inc. filed a Form 8K on August 10, 2026. The filing is a standard SEC disclosure for significant corporate events. The brief note from Investing.com provides no further details about the content of the 8K.

Theravance's Once-Daily COPD Treatment Posts $70.7M Sales

Theravance Bio: Q2 Earnings Snapshot

Theravance Biopharma Inc. (TBPH) reported a second-quarter loss of $5.9 million, or 11 cents per share. Adjusted earnings were 19 cents per share, while the company's revenue of $20.7 million surpassed analyst expectations of $19.8 million. This financial snapshot highlights their performance in the …

Theravance Biopharma (TBPH) Earnings Date and Reports 2026

Theravance Biopharma, Inc. $TBPH Shares Acquired by Dimensional Fund Advisors LP

Theravance Biopharma, Inc. (TBPH) Stock Analysis: Strong Revenue Growth and High ROE Offer Intriguing Investment Prospects

TBPH: Zymeworks Cash Deal And CVR Will Shape Post Ampreloxetine Path

Theravance Biopharma's fair value has increased to $17.67, aligning closely with Zymeworks' $17 per share cash acquisition offer. Analysts are focusing on the implications of the deal, with bullish views highlighting the clear valuation anchor and durable cash flow, while bearish sentiments emphasize that …

Theravance Biopharma (TBPH) Expected to Announce Earnings on Tuesday

Arrowstreet Capital Limited Partnership Sells 635,711 Shares of Theravance Biopharma, Inc. $TBPH

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Rating of "Hold" from Analysts

(TBPH) Movement as an Input in Quant Signal Sets

Theravance Biopharma Inc. (NASDAQ: TBPH) is showing neutral near and mid-term readings with a potential long-term positive bias, according to Stock Traders Daily's quantitative analysis. The report highlights a significant 45.6:1 risk-reward short setup and provides specific entry, target, and stop-loss zones for various …

Theravance Biopharma Inc (TBPH) Financial Health: Profitability & Balance Sheet Analysis

Theravance Biopharma Inc (TBPH) has a strong financial score of 7.72, placing it robustly within the Pharmaceuticals industry. The company reported a significant 15.02% year-over-year increase in quarterly revenue, reaching $17.70M, and its net profit surged by 63.67% year-over-year. This analysis highlights TBPH's robust …

ETFs Investing in Theravance Biopharma Inc Stocks

This article lists various Exchange Traded Funds (ETFs) that hold shares of Theravance Biopharma Inc. Each ETF entry includes details such as market value, weight of Theravance Biopharma stock in the fund, issuer, management style, focus, expense ratio, AUM, price, change, relative volume, and …

TBPH|Theravance Biopharma Inc|Price:16.865|Chg%:+0.005

This article provides a comprehensive stock analysis of Theravance Biopharma Inc (TBPH) using the TradingKey Stock Score. It highlights the company's strong fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. While institutional ownership is high, analysts have rated it as "Hold" …

103,000 Shares in Theravance Biopharma, Inc. $TBPH Purchased by Rangeley Capital LLC

Theravance Biopharma Inc (TBPH) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an in-depth analysis of Theravance Biopharma Inc's (TBPH) shareholder structure, detailing major individual and institutional holdings. It breaks down shareholders by type and lists the changes in institutional shareholding over recent quarters, alongside related ETF holdings. Key data includes top shareholders …

Theravance Biopharma Inc Revenue Breakdown – LS:A1137V

Theravance Biopharma Inc (A1137V) generated 91.50 million EUR in revenue last year, primarily from its Human Therapeutics segment. The United States was the largest contributor to this revenue, accounting for 63.83 million EUR. This represents an increase from the previous year's total revenue of …

Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma

TBPH Forecast — Price Target — Prediction for 2027

TBPH Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline - Earnings Beat Streak